3/16/2023 0 Comments Stock tcelPurchasers of the Offered Shares will not be entitled to a refundĪnd could lose their entire investments. All proceeds from this offering willīecome immediately available to us and may be used as they are accepted. This offering is being conducted on a best-efforts basis, which means that there is no minimum number of Offered Shares that must be soldīy us for this offering to close thus, we may receive no or minimal proceeds from this offering. Purchase of $1,000 of the Offered Shares is required in this offering any additional purchase must be in an amount of at least $500. Per share, pursuant to Tier 1 of Regulation A of the United States Securities and Exchange Commission (the “SEC”). Is offering for sale a maximum of 100,000,000 shares of its common stock (the “Offered Shares”), at a fixed price of $._ Of our sale to you that contains the URL where the Final Offering Circular or the offering statement in which such Final Offering Circularīy this Offering Circular, XTRA Bitcoin, Inc., a Wyoming corporation, We mayĮlect to satisfy our obligation to deliver a Final Offering Circular by sending you a notice within two business days after the completion Which such offer, solicitation or sale would be unlawful before registration or qualification under the laws of any such state. Not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sales of these securities in any state in May offers to buy be accepted before the offering statement filed with the SEC is qualified. Information contained in this Preliminary Offering Circular is subject to completion or amendment. To Regulation A relating to these securities has been filed with the United States Securities and Exchange Commission (the “SEC”). PART II - INFORMATION REQUIRED IN OFFERING CIRCULAR Our drug discovery capabilities allow us to discover and fully characterize immune receptors-TCRs and antibodies-to develop as therapeutic products.Get inside Wall Street with StreetInsider Premium. By combining our proprietary immunosequencing technology, computational modeling, and machine learning capabilities, we are making significant advances in how we can better detect and treat disease. Our goal is to make the diagnosis and monitoring of disease more accurate and reliable. We do this by building a map that links trillions of TCRs with millions of disease antigens. We use the exquisite specificity of T-cell receptors (TCRs) to discover and validate T-cell signatures of disease-from infectious diseases to autoimmune conditions and in the future, potentially to cancer. By reading and decoding the adaptive immune system, we aim to translate into the clinic the natural capability of the immune system to recognize and fight disease. These same cells are also involved in different autoimmune disorders. Specialized cells of the adaptive immune system, T and B cells, constantly respond to infections and cancer. Adaptive has partnered with Microsoft to map and decode the human immune system.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |